WAM
PCRX icon

Wakefield Asset Management’s Pacira BioSciences PCRX Stock Holding History

Wakefield Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,164
Closed -$441K – 193
2020
Q1 		$441K Buy
+13,164
New +$547K 0.24% 98

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Wakefield Asset Management's PCRX Position: Q2 2020 in Review

Wakefield Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2020, closing a stake of 13,164 shares — an estimated $441K sold.

Wakefield Asset Management first reported a position in PCRX in Q1 2020 and held it in 1 quarter. The position peaked at $441K in Q1 2020. 248 funds tracked by Wall St. Rank hold PCRX as of Q2 2020.

  • Wakefield Asset Management reported no remaining Pacira BioSciences position as of Q2 2020 after selling out during the quarter.
  • Wakefield Asset Management sold 13,164 Pacira BioSciences shares in Q2 2020, an estimated $441K.
  • Wakefield Asset Management first reported a position in Pacira BioSciences in Q1 2020 and held it in 1 quarter.
  • Wakefield Asset Management's Pacira BioSciences position peaked at $441K in Q1 2020.
  • 248 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2020.

Based on Wakefield Asset Management's 13F filing for Q2 2020, filed 28 Jul 2020.